Purpose: Despite significant growth of opioid prescriptions, only limited data are available regarding the comparative safety of long-acting opioids for chronic non-cancer pain. Recent data suggest that transdermal fentanyl and oxycodone CR may have greater toxicity than morphine SR in patients with non-cancer pain. Thus, we compared the risk of out-of-hospital deaths in patients with non-cancer pain filling prescriptions for transdermal fentanyl or oxycodone CR with that for morphine SR.
20 034 and 151 218 visits to US emergency rooms involving fentanyl and oxycodone products, respectively. 7 Medical personnel have raised similar concerns regarding increasing use and potential toxicity of opioids in Europe and Canada. 8, 9 Despite these trends, prescriptions for long-acting opioids treating chronic non-cancer pain have continued to increase over the past two decades. 10, 11 Amidst larger concerns about opioid safety, scholars, and government institutions have issued alerts and recommendations regarding two opioids with specific administration-transdermal fentanyl and oxycodone CR-indicating that these drugs may pose greater risks for toxicity compared with more established long-acting opioids, such as morphine SR, 7, 12 the preferred long-acting opioid for severe pain by US practitioners 13 and a prototypical mu opioid agonist.
14 Risks for overdose among transdermal fentanyl users most plausibly are related to its route of administration and pharmacodynamics, which produce significant inter-individual variability. Factors such as body surface area and temperature can influence the clearance and variability of transdermal absorption of fentanyl. 15, 16 Furthermore, fentanyl is one hundred times more potent than morphine, and the transdermal patches release the drug for 2 to 3 days, with variable bioavailability. 16 Ecological studies have raised questions regarding the safety of oxycodone CR. After a Canadian province added long-acting oxycodone to formularies, an initial report found markedly increased opioid-related mortality. 12 Follow-up reports showed a 264% increased risk of drug overdose deaths attributed to oxycodone between 2003 and 2009. 17 Another study found that the risk of death for oxycodone users was more than twice that of comparable hydrocodone users. 18 However, it is not clear whether or not these findings reflect a secular trend of increasing prescriptions or if they are due to differences in relative opioid doses.
Despite these concerns about the safety of transdermal fentanyl and oxycodone CR, we are unaware of direct comparisons of these drugs with other long-acting opioids in patients with non-cancer pain.
Indeed, a panel of experts has called for more research on the comparative benefits and harms of different opioids. 19 Thus, we conducted a retrospective cohort study to compare the relative mortality in users of transdermal fentanyl and oxycodone CR with that for morphine SR. 
| PATIENTS AND METHODS

| Use of opioid and dose equivalences
We studied the long-acting opioid analgesics transdermal fentanyl and oxycodone CR with morphine SR as the comparator. We excluded patients taking methadone or buprenorphine, which are often markers for substance abuse disorder treatment. Our calculations for opioid dose-equivalences were based upon a previously published study of chronic opioid therapy for non-cancer pain in adults. 22 
| Opioid indication
We assigned a single indication (the probable reason for which the opioid was prescribed) for each prescription. We used an algorithm that prioritized temporal proximity to the prescription fill date, type of medical care (primary over secondary diagnoses), and the specific indication in the following order: back pain, other musculoskeletal/soft tissue pain, abdominal pain, headache, other neurological pain, infection, trauma, dental procedures, and other procedures. 
| End-points
The primary study endpoint was death occurring outside of hospital during study follow-up.
These deaths were further classified as (1) unintentional opioid toxicity deaths-the definition of which has a positive predictive value of >90%, 23 and (2) other deaths-defined as death not attributed to the use of opioids.
| Statistical analysis
We used proportional hazard regression models to estimate the hazard ratios (HR) for transdermal fentanyl and oxycodone SR use compared with morphine SR use. The HRs were adjusted for potential differences among the groups using propensity scores that included 145 covariates such as demographic variables, calendar time, opioid indication, use of other opioids, cardiovascular medications and diagnoses, psychiatric medications and diagnoses, respiratory conditions, musculoskeletal diseases, indicators of frailty, other comorbidities, and medical care utilization (Appendix, Table 1 ). Because concurrent use of benzodiazepines is associated with a higher risk of overdose death, we included this variable in the propensity scores. We estimated two different propensity scores (one for fentanyl and one for oxycodone) using morphine SR as reference. The first one calculated the probability of assignment to transdermal fentanyl, and the second one calculated the probability of assignment to oxycodone SR given the same set of 145 covariates. To assess the performance of the propensity scores, we compared the distribution of the study variables after inverse probability of treatment weighting (Appendix tables 2-5). To avoid the inclusion of patients whose treatment was effectively predetermined, we trimmed subjects whose propensity scores were less than the first or greater than the 99 th percentiles.
To adjust for potential confounders, we used stratified proportional hazard models with the strata defined by propensity score deciles. These models included drug exposure as time-dependent covariates; eight models included study opioid dose (in estimated morphine equivalent mg/d) as an additional covariate. To assess for robustness of the results, we performed three sensitivity analyses.
First, we calculated HRs for propensity score-matched observations.
Second, we conducted analyses restricted to ≤365 days of followup. Third, to examine whether drug abuse affected the relationship between the study drugs and mortality differentially, we conducted a sensitivity analysis in which follow-up was not censored for codes indicating substance abuse. All analyses were completed using STATA 13.1 (StataCorp LP, College Station, TX). All P-values are two sided.
| RESULTS
Of 50 658 patients who filled prescriptions for long-acting opioids for non-cancer pain, 8717 filled a prescription for transdermal fentanyl, 14 118 for oxycodone CR, and 27 823 for morphine SR. Patients were predominantly female and Caucasian. The majority were disabled; back pain and other musculoskeletal conditions were the most common indications for prescription of long-acting opioids. Although the calculated median daily dose for oxycodone CR patients was greater than that for morphine SR (120 mg vs 90 mg), demographic characteristics, comorbidities, and use of other medications were distributed similarly among the three study groups. The three groups also had similar rates of medical care utilization measured as hospital stay in the previous year and emergency room and inpatient encounters due to overdose in the previous year (Table 1) .
There were 689 out-of-hospital deaths during 44 385 personyears of follow-up, and the all-cause mortality rate was 155 per 10 000 patient-years. Table 2 presents the risk of death during current use of transdermal fentanyl and morphine SR, by type of death. Unadjusted mortality rates were similar in both groups, and the propensity score-adjusted all-cause mortality was not significantly different in compared with those receiving morphine SR. Table 3 presents the risk of death during current use of oxycodone CR and morphine SR, by type of death. Unadjusted mortality rates were higher in patients filling prescriptions for morphine SR, and the propensity score-adjusted all-cause mortality was 21% lower in patients filling oxycodone CR (aHR = 0.79, 95% C.I. 0.66-0.95) than in those filling prescriptions for morphine SR.
We found no significant differences in the risk of death from nonopioid related causes among fentanyl and morphine SR users Table 3) .
Sensitivity analyses that included propensity score-matched cohorts and restriction to the first 365 days of observation gave similar results (Table 4 ). An analysis restricting the outcome to deaths from unintentional opioid toxicity/overdose also showed lower risk in patients using oxycodone CR (aHR = 0.60, 95% C.I. = 0.38-0.94) compared with morphine SR.
Similar results were obtained when analyses were restricted to the first year of drug exposure and the mortality rates were very similar in a sensitivity analysis in which follow-up did not end due to codes indicating addiction. (Appendix Table 6 ).
As a check on the dose-equivalents for study opioids, two models did not include opioid doses (Tables 2 and 3 ). In these analyses, the HRs for oxycodone remained less than one, but they were no longer statistically significant.
| DISCUSSION
Our study generated three main findings: (1) the use of long-acting opioids in study patients with non-cancer pain was associated with high rates of out-of-hospital mortality; this rate contrasts with the out-of- reported an all-cause mortality rate of 320/10 000 person-years. 25 Similarly, a study in patients from the Department of Veterans Affairs receiving prescriptions for methadone and long-acting morphine reported mortality rates between 200 and 1300 per 10 000 person-years (although this study did not exclude patients with cancer or deaths that occurred in hospital). 26 Our second finding was surprising. In contrast to our hypothesis, out-of-hospital mortality rates associated with the use of transdermal fentanyl and oxycodone CR were not higher than those in patients using morphine SR. One explanation may be that our study focused on the mortality risk associated with therapeutic use by excluding patients with previous evidence of substance abuse, whereas in other ecologic b Adjusted for propensity scores (by deciles) and morphine equivalent dose.
Abbreviations: HR, hazard ratio; CI, 95% confidence interval.
studies, a significant number of deaths attributed to fentanyl and oxycodone CR use are related to abuse (rather than therapeutic use). 27 Alternately, this finding may indicate that dose-rather than other pharmacologic variables-may be the main determinant of opioid toxicity; equivalent doses of either fentanyl or morphine confer similar risks.
Our third finding was that patients prescribed long-acting oxycodone had lower mortality rates than those prescribed morphine SR.
Although these results coincided with those reported in a smaller study in Oregon, 28 we observed a smaller difference between the two mortality rates. This finding could reflect better safety for oxycodone CR;
however, other reasons should be considered. Pharmacokinetic differences between the study drugs potentially could explain the reduced risk of death for oxycodone. The accumulation of the active metabolites of morphine in patients with renal impairment, particular M6G, could increase the risk of morphine toxicity. 29 Although this would suggest risk should also be lower with fentanyl, it could have continued to be delivered even when the patient became sedated, unless the patch was removed, thus increasing risk by another mechanism. However, the fact that oxycodone and its metabolites also accumulate in patients with renal impairment 30 argues against this explanation.
Another potential explanation relates to the accuracy of widely accepted conversion factors for opioid doses that equate 20 mg of oxycodone to 30 mg of morphine. In the study cohort, the median prescribed dose for oxycodone CR was 80 mg/day, which equates to 120 mg morphine-equivalents, which was greater than the 90 mg/day for morphine SR. Only after statistically adjusting for this higher dose of oxycodone did the mortality difference between the two opioids become significant.
The rates of opioid diversion may have differed among the three study opioids, resulting in differential exposure misclassification.
Although we sought to reduce such misclassification by excluding patients with any recorded evidence of drug abuse, some diversion of opioids may have occurred. Given the study data, it was not possible to estimate the extent of such diversion.
Three important concerns pertinent to all pharmacoepidemiologic studies should be considered: misclassification, confounding, and power.
We excluded patients with potentially terminal conditions and those with a history of drug abuse to minimize the risk of misclassification resulting from deaths unrelated to the therapeutic use of opioids. We took several steps to minimize potential confounding. First, we performed a careful selection of an extensive number of potential covariates. Second, we used propensity scores for adjustments. 31 Third, we performed sensitivity analyses including propensity score matched results and analyses restricted to the first 365 days of observation; all yielded similar results. Fourth, we conducted an analysis of the risk of death classified as "other deaths," for which, as expected, there were no statistical differences between the three opioids.
Nevertheless, residual confounding is possible. To address power concerns, the study included a large defined population followed for several years.
There were several other potential limitations. The study was restricted to patients enrolled in the TennCare program, and Tennessee is among the states with the highest rates of opioid prescriptions in the USA. 32 Thus, the findings may not be generalizable to other populations.
We restricted the study to three long-acting opioids commonly prescribed in routine clinical practice, but whose relative safety has been questioned; therefore, the findings may not be generalizable to short-acting forms of these opioids. We did not directly compare oxycodone and fentanyl because the a priori protocol specified comparisons of fentanyl and oxycodone with morphine, the most commonly prescribed long-acting opioid for non-cancer pain. Oxycodone is metabolized by both CYP3A4 and CYP2D6. Although the propensity score did not include a variable for concurrent use of CYP2D6 inhibitors, it did include indicators of current use of the antidepressants fluoxetine and paroxetine, the most commonly prescribed 2D6 inhibitors in the study population. We did account for use of short-acting opioids but did not include their doses in the propensity score because these drugs, when used with long-acting opioids, often are taken as needed for breakthrough pain. Finally, while we sought to exclude patients filling prescriptions for methadone, it is possible that some could have received it through the Medication-Assisted Treatment program for opioid dependence disorder. Further, we could not estimate rates of drug diversion; thus, we cannot exclude differential rates on drug diversion among study drug users. However, by excluding patients and person-time with recorded evidence of substance abuse, we decreased the likelihood of this source of misclassification.
In conclusion, a cohort of patients with no evidence of life-threatening illness and non-cancer pain treated with long-acting opioids had high rates of out-of-hospital mortality. We did not find evidence that the risk of out-of-hospital death associated with transdermal fentanyl or oxycodone CR was higher than that for morphine SR. There was a statistically significant, but small decrease in the risk of out-of-hospital mortality in patients who filled a prescription for oxycodone CR compared with those who filled a prescription for morphine SR.
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